ETF Evaluator:
Corgi Genomics & Precision Medicine ETF ()
Follow This ETF
(as of )
Best Performing in Health Over the Last Year
| 129.4% | Virtus LifeSci Biotech Clinical Trls ETF (BBC) |
| 94.1% | ALPS Medical Breakthroughs ETF (SBIO) |
| 88.4% | F/m Emerald Life Sciences Innovation ETF (LFSC) |
| 72.5% | State Street® SPDR® S&P® Biotech ETF (XBI) |
| 65.8% | State Street® SPDR® S&P® PhrmctlsETF (XPH) |
Risk
Index
Risk
Index
ETF Details
Corgi Genomics & Precision Medicine ETF Overview
Corgi Genomics & Precision Medicine ETF (GNMX) is an actively managed Sector Equity Health exchange-traded fund (ETF). Corgi Funds launched the ETF in 2026.
The investment seeks capital appreciation.
The fund is an ETF that seeks to meet its objective by having Corgi Strategies, LLC actively manage the fund and, under ordinary market conditions, invest at least 80% of its net assets (plus any borrowings for investment purposes) in a portfolio of companies materially involved in the research, development, and commercialization of genomics and precision medicine technologies that enable improved disease detection, identifying and grouping patients based on genetic, molecular, or clinical characteristics to guide treatment decisions, targeted therapies, and data-driven healthcare. It is non-diversified.
About Corgi Genomics & Precision Medicine ETF (GNMX)
There are 3 members of the management team with an average tenure of 0.24 years: Isaac Hargett (2026), Anthony Crinieri (2026) and Miles Braden (2026). Management tenure is more important for actively managed ETFs than passive index ETFs.
Corgi Genomics & Precision Medicine ETF has 59 securities in its portfolio. The top 10 holdings constitute 44.2% of the ETF’s assets. The ETF meets the SEC requirement of being classified as a nondiversified fund. The ETF is not considered to have an ESG focus with its investment selection and management.
Corgi Genomics & Precision Medicine ETF is part of the Equity global asset class and is within the Sector Equity ETF group. Corgi Genomics & Precision Medicine ETF has 7.1% of its portfolio invested in foreign issues. The overall assets allocated to domestic stock is 89.7% There is 7.1% allocated to foreign stock, and 0.0% is allocated to preferred stocks. The bond allocation as a percentage of total assets is 0.0% (0.0% domestic bond, 0.0% foreign bond and 0.0% convertible bond). Corgi Genomics & Precision Medicine ETF has 3.3% of the portfolio in cash.
Assets Under Management
The fund has $1 million in total assets, which is below the $1 billion average for the Health category. Normally, lower assets under management translates to higher average expense ratios, and greater total assets are desired. However, for some investment categories, such as small-cap investing, it may be difficult for the manager to fully employ the desired active strategy if assets grow too large or too quickly.
GNMX Performance and Fees
The expense ratio measures how much of a fund’s assets are used for administrative expenses and operating expenses, including adviser fees and fees for the transfer agent and custodial services. The Corgi Genomics & Precision Medicine ETF expense ratio is below average compared to funds in the Health category. Corgi Genomics & Precision Medicine ETF has an expense ratio of 0.35%, which is 32% lower than its category average, making the fund expense ratio grade a A. While it is difficult to predict returns, it is known that high annual expense ratios reduce your rate of return, and excessive fees are difficult to overcome. Active management normally comes with higher expense ratios than passive index management. Certain investment categories such as small company and foreign also normally have higher expense ratios. It is best to compare fund expense ratios against the category averages for meaningful assessments.
High portfolio turnover can translate to higher expenses and lower aftertax returns. Corgi Genomics & Precision Medicine ETF has a portfolio turnover rate of 0%, which indicates that it holds its assets around /years. By way of comparison, the average portfolio turnover is 45% for the Health category.
Recently, in the month of July 2026, Corgi Genomics & Precision Medicine ETF returned -4.4%, which earned it a grade of F, as the Health category had an average return of -0.1%. The letter grades of A, B, C, D and F are based upon relative rankings within the investment category. A grade of A, for example, would indicate that the return is in the highest 20% for that time period compared to all ETFs in that category.
Corgi Genomics & Precision Medicine ETF has a trailing yield of 0.00%, which is below the 1.10% category average.
The fund normally distributes its income annually and its capital gains annually.
It’s natural to seek the best-performing investments, but you must consider the relationship between risk and return and the impact of costs and taxes on your realized returns.
For more ETF grades, analysis and screening tools to help your investment discovery, join AAII for a $2, full-access trial. Learn more here: https://invest.aaii.com/membership.
Otherwise, for more information about Corgi Genomics & Precision Medicine ETF, including its riskiness, submit your email to unlock the rest of the article.
Gain access to exclusive AAII member-only content.
GNMX Trailing NAV Total Returns Data as of 7/31/26
| Last Month |
Last Quarter |
Ann'l. 1Yr |
Ann'l. 3Yr |
Ann'l. 5Yr |
Ann'l. 10Yr |
|
| GNMX Return (NAV) | -4.4% | na | na | na | na | na |
| GNMX Return (Price) | -4.4% | na | na | na | na | na |
| NAV +/- Price Return | -0.062% | na | na | na | na | na |
| Health Avg | -0.1% | 11.2% | 36.9% | 9.9% | 1.6% | 8.7% |
| GNMX Grade (NAV) | F | na | na | na | na | na |
| +/- Category (NAV) | -4.4% | na | na | na | na | na |
| GNMX Tax-Cost Ratio | na | na | na | na | na | na |
GNMX Annual NAV Total ReturnsData as of 7/31/26
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| GNMX Return (NAV) | na | na | na | na | na | na | na | na | na | na | na |
| GNMX Return (Price) | na | na | na | na | na | na | na | na | na | na | na |
| NAV +/- Price Ret | na | na | na | na | na | na | na | na | na | na | na |
| Health Avg | 9.7% | 21.8% | 0.1% | 2.2% | -16.3% | 4.3% | 30.5% | 25.4% | -1.5% | 26.5% | -10.2% |
| GNMX Grade (NAV) | na | na | na | na | na | na | na | na | na | na | na |
| +/- Category | na | na | na | na | na | na | na | na | na | na | na |
| Risk Measures | |
| Beta: | na |
| R-Squared: | na |
| Standard Deviation: | na |
| Category Risk Index: | na |
| Category Risk Rating: | |
| Total Risk Index: | na |
| Total Risk Rating: | |
| Portfolio Characteristics | |
| Yield: | -- |
| Total Assets: | $ 2 Mil |
| Share Class Assets: | $ 2 Mil |
| Turnover: | na |
| Expense Ratio: | 0.35% |
| Index Fund: | No |
| Index Tracked: | N/A |
| Index Weighting: | 100% |
| Leveraged: | No |
| Socially Responsible Fund: | No |
| Capital Gains Distribution Frequency: | Annually |
| Income Distribution Frequency: | Annually |
Management Team
| Number of Managers: 3 | |||
| Longest Tenure: 0.2 years | |||
| Average Tenure: 0.2 years | |||
| Managers (Year): Hargett Isaac (2026), Crinieri Anthony (2026), Braden Miles (2026) | |||
Portfolio Composition (as of 7/31/26)
| # of Holdings: | 59 |
| % in Top 10 Holdings: | 44.2% |
| Fund is Non-Diversified: | Yes |
| % in Foreign Issues: | 7.1% |
Portfolio Allocation |
|
| Domestic Stock: | 89.7% |
| Foreign Stock: | 7.1% |
| Preferred Stock: | 0.0% |
| Domestic Bond: | 0.0% |
| Foreign Bond: | 0.0% |
| Convertible Bond: | 0.0% |
| Other: | -0.0% |
| Cash: | 3.3% |
Purchase Information
| Legal Structure: | Open Ended Investment Company |
| Fund Family: | Corgi Funds |
| Phone Number: | 855-552-6744 |
| Website: | |
| Inception Date: | May 5, 2026 |
Expenses and Fees
| Expense Ratio (%): | 0.35% (Rating: Below Avg) |
| Category Average Expense Ratio (%): | 0.52% |
